1-630-590-7762
CHICAGO, Nov. 29, 2016 /PRNewswire/ -- IBM (NYSE: IBM) today announced at the Radiological Society of North America Annual Meeting (RSNA 2016) it will preview new imaging solutions from Watson Health and Merge Healthcare (Merge; an IBM Company) designed to help healthcare providers pursue personalized approaches to patient diagnosis, treatment, and monitoring. The solutions benefit from more than a decade of machine learning and artificial intelligence (AI) work conducted in IBM Research. Further, IBM Research has partnered with the Radiological Society to debut a live demonstration of how Watson understands, reasons and learns from imaging information.
Medical images are by far the largest and fastest-growing data source in the healthcare industry -- IBM researchers estimate that they account for at least 90% of all medical data today -- but they also present challenges that need to be addressed. The volume of medical images can be overwhelming to even the most sophisticated specialists; radiologists in some hospital emergency rooms are presented with thousands of images each day.1
Tools to help clinicians extract insights from medical images remain limited, requiring most analysis to be done manually. This has created an opportunity to analyze and cross-reference medical images against a deep trove of lab results, electronic health records, genomic tests, clinical studies and other health-related data sources to enable providers to compare new medical images with a patient's image history as well as populations of similar patients to detect changes and anomalies.
"The breadth and depth of Watson-powered solutions on display at RSNA 2016 from Watson Health's imaging group and from Merge are unmatched among the AI community, and showcase how IBM is bringing cognitive computing to healthcare in clinically meaningful ways," said Anne LeGrand, Vice President of Imaging for IBM Watson Health.
Watson Health will show:
Merge will show:
"Watson cognitive computing is ideally suited to support radiologists on their journey 'Beyond Imaging' to practices that address the needs of patient populations, deliver improved patient outcomes, and demonstrate real-world value," said Nancy Koenig, General Manager of Merge Healthcare. "This week at RSNA, Merge is proud to unveil solutions for providers that enable the first steps on the cognitive care journey, addressing breast cancer, lung cancer, and trauma patients in the ER."
RSNA and IBM Research Show Physicians How Watson Understands, Reasons and Learns
IBM Research will show physicians how Watson might reduce the time to diagnosis and increase efficiency in provider workflows. Radiologists select cases from a variety of imaging topics, make their diagnosis, and see how a Watson solution attempts to assist the same case as it understands, reasons and learns from text- and imaging data in real time.
The live demonstration showcases more than a decade of work by IBM Research's top medical imaging, text mining, and AI data scientists. The demo is able to analyze patient data culled from thousands of data sources and present insights in a compact summary report intended to help clinicians efficiently reach a differential diagnosis. For example, the technology featured in the demo uses deep learning to recognize positions in the body for major anatomical structures (such as in a CT imaging study) and detects anomalies (such as dissections in the aorta, or embolisms in pulmonary arteries). Combining imaging and clinical data with clinical knowledge, it performs clinical inference on the patient's condition and its management, pre-assembling relevant information in a simple online format for a diagnosing physician to consider.
IBM is also showcasing at RSNA 2016 its ecosystem approach to innovation, including the global Watson Health medical imaging collaborative and work with Siemens Healthineers to introduce Population Health Management solutions worldwide. For more information about IBM's presence at RSNA 2016, visit the Merge web site and follow @MergeHealthcare for #RSNA16 updates throughout the conference.
The Watson Health Imaging and Merge demonstrations are cognitive healthcare works-in-progress in Booth 2538 in South Hall A.2
About IBM Research
For more than seven decades, IBM Research has continued to define the future of information technology with more than 3,000 researchers in 12 labs located across six continents. Scientists from IBM Research have produced six Nobel Laureates, 10 U.S. National Medals of Technology, five U.S. National Medals of Science, six Turing Awards, 19 inductees in the National Academy of Sciences and 20 inductees into the U.S. National Inventors Hall of Fame. For more information about IBM Research, visit www.research.ibm.com.
About IBM Watson Health
Watson is the first commercially available cognitive computing capability representing a new era in computing. The system, delivered through the cloud, analyzes high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. Watson continuously learns, gaining in value and knowledge over time, from previous interactions. In April 2015, the company launched IBM Watson Health and the Watson Health Cloud platform. IBM Watson Health is helping to improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily. The Watson Health Cloud can mask patient identities and allow for information to be shared and combined with a dynamic and constantly growing aggregated view of clinical research and social health data. For more information on IBM Watson, visit: ibm.com/watson. For more information on IBM Watson Health, visit: ibm.com/watsonhealth.
Resources
Media Contacts:
Lorie Fiber/Watson Health
lfiber@us.ibm.com
646-318-0575
Caroline Yu Vespi/IBM Research – Almaden
cvespi@us.ibm.com
925-212-9184
1 IBM Research estimate
2 These Watson Health Imaging and Merge solutions are not available for any commercial or non-commercial use in the United States and have not been evaluated by any regulatory agencies (such as USFDA) for safety or efficacy. Any demonstrated functionality, statements and claims related to capabilities are aspirational only and represent a vision of a possible future technology. All statements regarding IBM's future direction and intent are subject to change or withdrawal without notice, and represent goals and objectives only.
Photo - http://photos.prnewswire.com/prnh/20161128/443483
Photo - http://photos.prnewswire.com/prnh/20161129/443678
Photo - http://photos.prnewswire.com/prnh/20161129/443679
Logo - http://photos.prnewswire.com/prnh/20090416/IBMLOGO
SOURCE IBM
